Plocabulin is under clinical development by Pharma Mar and currently in Phase I for Adenocarcinoma. According to GlobalData, Phase I drugs for Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Plocabulin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Plocabulin overview
Plocabulin (PM-184, PM-060184) is under development for the treatment of refractory advanced solid tumors including advanced gastrointestinal stromal tumor (GIST), biliary tract adenocarcinoma, thymic cancer, cervix carcinoma, epithelial ovarian cancer including primary peritoneal disease, fallopian tube carcinomas, endometrial adenocarcinomas, advanced or metastatic head and neck cancer, non-small cell lung cancer (NSCLC), germ cell tumors (GCTs), biliary tract adenocarcinoma, urothelial cancer and HER2 negative metastatic breast cancer (second line) and metastatic colorectal cancer. The drug candidate is administered. It is a marine sponge (Lithoplocamia lithistoides) derived, synthetically produced compound. It is a tubulin-binding agent. The drug candidate was under development for the treatment of hormone-receptor positive advanced breast cancer.
Pharma Mar overview
Pharma Mar discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed products include Yondelis (trabectedin) an antitumor agent indicated for the treatment of soft tissue sarcoma and relapsed ovarian cancer in combination with doxorubicin HCl liposome injection; Aplidin (plitidepsin), an anticancer agent for the treatment of multiple myeloma; and Zepzelca (lurbinectedin) for small cell lung cancer. Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others. It also offers kits used for diagnosis of influenza A and B and respiratory syncytial virus. Its development pipeline includes PM14 for solid tumors, among others. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, and the US, among others. Pharma Mar is headquartered in Madrid, Spain.
For a complete picture of Plocabulin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.